Offene Studien Rezidiv
| Name | Titel |
|---|---|
AGO-Ovar 2.29 | Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer |
| AGO-Ovar 2.31 / OREO | Studie der Phase IIIb zur erneuten Erhaltungstherapie mit Olaparib bei Patientinnen mit epithelialem Ovarialkarzinom, die mit einem PARPi vorbehandelt wurden und auf eine wiederholte platinhaltige Chemotherapie ansprechen (OReO) |
| AGO-Ovar 2.32 | Trabectedin/PLD versus continuation of platinum-based chemotherapy in patients with disease stabilization and no symptom benefit under platinum-based chemotherapy for recurrent ovarian cancer. |
| DICE | An international, multi-centre, randomised phase II study to assess the efficacy of TAK228 as a single agent and in combination with intravenous weekly paclitaxel compared with weekly paclitaxel in women with advanced/recurrent clear cell, endometrioid and high grade serous carcinoma of the ovary |
| ENGOT-EN 5 / SIENDO | A randomized phase III trial of maintenance with Selinexor / placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer |
| HELP-ER | Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer |
| INNOVATE-3 / EF-28 | Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) |
| IOVANCE C-145-04 | A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma |
| PazoDoble II | Pazopanib versus Pazopanib plus Gemcitabin in Patientinnen mit rezidivierten oder metastasierten uterinen Leiomyosarkomen oder uterinen Carzinosarkomen |